乳腺癌患者血浆尿激酶型纤溶酶原激活系统的变化及其意义

目的 :观察乳腺癌患者血浆尿激酶型纤溶酶原激活物 (u -PA)及其特异性受体 (u -PAR)和纤溶酶原激活物抑制物 - 1 (PAI- 1 )含量的变化及其与肿瘤转移和预后的关系。方法 :用ELISA法测定 2 2例乳腺癌患者和 2 1例正常人血浆中u -PA、u -PAR和PAI- 1含量。结果 :乳腺癌患者的血浆u -PA、u -PAR和PAI - 1含量均显著升高 (P <0 .0 5～ 0 .0 1 ) ;中、晚期组u -PA显著高于早期组 (P <0 .0 5 ) ,已转移组u -PA、u -PAR和PAI- 1较未转移组显著升高 (P <0 .0 5～ 0 .0 1 )。结论 :乳腺癌患者血浆中u -PA、u -PAR和PAI - 1含量不同程度升高 ,并与肿瘤转移和预后相关

Variation and clinical significance of urokinase-type plasminogen activator system in mammary cancer

Objective: To investigate the variation of the plasma concentration of urokinase-type plasminogen activator (u-PA),urokinase-type plasminogen activator receptor (u-PAR) and plasminogen activator inhibitor-1 (PAI-1) in mammary cancer and their relationship with tumorous metastasis and prognosis. Methods: The levels of u-PA,u-PAR and PAI-1 in 22 patients with the malignant tumor and 21 normals were measured by ELISA.Results: u-PA,u-PAR and PAI-1 levels of mammary cancer significantly increased ( P <0.05～0.01);u-PA level in mid stage or advanced stage group was statistical higher than that of early stage group( P <0.05),u-PA,u-PAR and PAI-1 levels in the metastasis group was significantly higher than that of non- metastasis group ( P <0.05～0.01). Conclusion: Levels of u-PA,u-PAR and PAI-1 increased significantly in mammary cancer,and the increase is related to tumorous metastasis and prognosis.